US 12,269,866 B2
Compositions and methods for the treatment of carboxyhemoglobinemia
Mark T. Gladwin, Baltimore, MD (US); and Jesus Tejero Bravo, Pittsburgh, PA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Nov. 8, 2023, as Appl. No. 18/504,534.
Application 18/504,534 is a continuation of application No. 16/951,529, filed on Nov. 18, 2020, granted, now 11,845,785.
Application 16/951,529 is a continuation of application No. 16/557,168, filed on Aug. 30, 2019, granted, now 10,851,153, issued on Dec. 1, 2020.
Application 16/557,168 is a continuation of application No. 15/726,779, filed on Oct. 6, 2017, granted, now 10,421,800, issued on Sep. 24, 2019.
Application 15/726,779 is a continuation of application No. 14/776,363, abandoned, previously published as PCT/US2014/023180, filed on Mar. 11, 2014.
Claims priority of provisional application 61/834,035, filed on Jun. 12, 2013.
Claims priority of provisional application 61/799,155, filed on Mar. 15, 2013.
Prior Publication US 2024/0083979 A1, Mar. 14, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/795 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61K 38/41 (2006.01)
CPC C07K 14/795 (2013.01) [A61K 9/0019 (2013.01); A61K 38/41 (2013.01); A61K 38/00 (2013.01)] 23 Claims
 
1. A human recombinant cytoglobin comprising a mutation at residue 81, and further comprising at least one of a C38S mutation and a C83S mutation.